BiOptic (ROCO:6850) ROE % Adjusted to Book Value: -0.61% (As of Dec. 2025)


ROCO:6850 BiOptic Inc ROCO:6850
92 GF Score
Price NT$35.00
GF Value NT$44.91
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BiOptic ROE % Adjusted to Book Value?

BiOptic ROCO:6850 92 ROE % Adjusted to Book Value is -0.61% as of Dec. 2025. GuruFocus rates ROCO:6850 with a GF Score™ of 92/100 and a GF Value™ of NT$44.91 (Modestly Undervalued). The stock has 4 warning signs investors should review.

BiOptic's ROE % for the quarter that ended in Dec. 2025 was -1.82%. BiOptic's PB Ratio for the quarter that ended in Dec. 2025 was 2.98. BiOptic's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 was -0.61%.

BiOptic ROE % Adjusted to Book Value Related Terms

BiOptic ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for BiOptic's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BiOptic ROE % Adjusted to Book Value Chart

BiOptic Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial 5.76 5.77 2.88 1.74 0.09

BiOptic Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.16 0.84 2.57 0.79 -0.61

ROCO:6850 vs VRTX, REGN, ALNY: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, BiOptic's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BiOptic ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BiOptic's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where BiOptic's ROE % Adjusted to Book Value falls into.


ROCO:6850
92GF Score
BiOptic Inc ROCO:6850
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BiOptic ROE % Adjusted to Book Value Calculation

BiOptic's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.27% / 2.98
=0.09%

BiOptic's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-1.82% / 2.98
=-0.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -0.61% mean?
BiOptic (ROCO:6850) has a ROE % Adjusted to Book Value of -0.61% as of Dec. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BiOptic and its competitors.
Is BiOptic's ROE % Adjusted to Book Value too high?
BiOptic's current ROE % Adjusted to Book Value is -0.61%. Overall, BiOptic has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BiOptic's ROE % Adjusted to Book Value compare to VRTX and REGN?
BiOptic's ROE % Adjusted to Book Value of -0.61% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on BiOptic and its competitors. BiOptic's current ROE % Adjusted to Book Value is -0.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BiOptic stock overvalued right now?
Based on GuruFocus' analysis, BiOptic (ROCO:6850) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$44.91, compared to a current price of NT$35.00 — trading 22.1% below its estimated fair value. The current ROE % Adjusted to Book Value is -0.61%. BiOptic's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For BiOptic (ROCO:6850), the current ROE % Adjusted to Book Value is -0.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BiOptic (ROCO:6850) Overvalued in 2026?

Based on GuruFocus' analysis, BiOptic stock appears to be undervalued. The current stock price of NT$35.00 is trading 22.1% below its estimated GF Value™ of NT$44.91. GuruFocus considers BiOptic to be Modestly Undervalued.

Key valuation signals for ROCO:6850:

  • ROE % Adjusted to Book Value: -0.61%
  • GF Value™: NT$44.91 vs. price of NT$35.00 (22.1% below fair value)
  • GF Score™: 92/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6850 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BiOptic Business Description

Address No. 108-3, Minquan Road, 4th Floor, Xindian District, New Taipei, TWN, 23141
BiOptic Inc is a biotechnology instrumentation company that develops scientific products for research and clinical applications. It serves professionals and laboratories dedicated to life science research, clinical diagnostics, pharmaceutical and food industries, animal husbandry, and agriculture, performing diagnostic molecular genetic analyses.
92GF Score

Get the complete analysis for ROCO:6850

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.00
Price
NT$44.91
GF Value